The Medical Device Single Audit Program (MDSAP) has published Version 009 of MDSAP AU P0008 — Audit Time Determination Procedure, setting out the criteria recognised Auditing Organizations must use when determining the time required to audit medical device manufacturers.
The updated procedure has both a version date and effective date of 12 November 2026 and is managed by Health Canada’s Frédéric Hamelin.
Purpose of the Procedure
The purpose of MDSAP AU P0008 is to define the criteria recognised Auditing Organizations (AOs) must use to determine the audit time required to conduct regulatory audits of medical device manufacturers under MDSAP.
The procedure is intended to reduce the risk of different AOs calculating significantly different audit times for similar audit activities.
Version 009 Updates References and Formatting
According to the document history, Version 009:
migrates the procedure to a new template;
updates definitions to reflect the most current references;
introduces minor editorial changes throughout the document.
The update was approved by the Chair of the MDSAP Regulatory Authority Council on 12 November 2026.
Audit Time Must Be Documented
Recognised AOs must comply with the procedure together with applicable requirements of ISO/IEC 17021-1:2015 when calculating audit duration.
They must also maintain documented evidence supporting:
the audit time calculation;
any adjustments;
other relevant justifications.
This documentation must support the amount of audit time determined for each medical device manufacturing facility.
One Auditor Day Equals Eight Hours
The procedure defines an Auditor Day as:
8 hours, excluding breaks, meals and travel.
This definition provides a consistent basis for translating calculated audit hours into MDSAP auditor days.
Off-Site Audit Time
Time spent on activities such as:
preparation;
document review;
report writing;
is determined according to each AO’s own policies and procedures.
This off-site activity is distinct from the duration of the on-site audit itself.
Audit Duration Depends on the MDSAP Audit Cycle
MDSAP distinguishes several types of audits:
Initial Certification — Stage 1 and Stage 2;
Surveillance Audits;
Re-audits or Recertification Audits;
Special Audits.
The applicable scope and audit criteria depend on the type of audit being performed.
As a result, audit duration can vary across different points in the three-year MDSAP audit cycle.
Task-Based Audit Time Calculation
The MDSAP approach is based primarily on the number of applicable audit tasks.
The programme defines seven QMS processes, each containing a different number of audit tasks.
These include:
Management;
Device Marketing Authorization and Facility Registration;
Measurement, Analysis and Improvement;
Medical Device Adverse Events and Advisory Notices Reporting;
Design and Development;
Production and Service Controls;
Purchasing.
90 Potential Audit Tasks
The calculation table identifies a total of 90 MDSAP audit tasks across the seven processes.
Not all tasks necessarily apply to every manufacturer.
For example, where an organisation does not manufacture sterile devices and its products do not require installation or servicing, certain Production and Service Controls tasks may not apply.
Different Time Values Apply to Different Processes
The procedure assigns an expected number of minutes to each task depending on the process.
Examples include:
Management — 28.8 minutes per task;
Device Marketing Authorization and Facility Registration — 28.0 minutes;
Measurement, Analysis and Improvement — 30.4 minutes;
Medical Device Adverse Events and Advisory Notices Reporting — 30.4 minutes;
Design and Development — 16.8 minutes;
Production and Service Controls — 35.2 minutes;
Purchasing — 12 minutes.
The formula uses the number of applicable tasks multiplied by the assigned task duration to calculate total audit hours and auditor days.
Initial Certification Audits Receive an Additional 25%
For initial certification audits involving Stage 1 and Stage 2, the calculated audit time is increased by 25%.
This additional time accounts for Stage 1 activities that may be conducted off-site.
When the MDSAP AU F0008.2 calculation spreadsheet is used, the 25% increase is automatically applied.
Stage 1 and Stage 2 Can Be Combined Operationally
The AO determines how Stage 1 and Stage 2 tasks should be divided between:
off-site record review;
on-site verification.
The procedure allows elements of both stages to be combined so that a manufacturer may, where appropriate, have a single on-site visit.
Audit Duration Adjustments Are Permitted
Audit duration can be adjusted where specific conditions apply.
The procedure provides adjustment rules relating to:
Design and Development;
Production and Service Controls;
previously cited nonconformities;
critical suppliers;
multiple-site audits;
organisation size.
Design and Development Adjustments
Where an organisation does not conduct design and development activities, the Design and Development audit can be limited to specific tasks.
For manufacturers producing devices designed before regulatory design-control requirements and not actively designing new products, a reduced subset of tasks can also apply.
Software-containing devices may require duplication of certain design and development tasks.
Production and Service Controls May Be Reduced During Surveillance
For surveillance audits, where a manufacturing process was comprehensively audited earlier in the same MDSAP cycle and there have been no significant changes or indicators of concern, the time allocated to that process may be reduced.
However, the reduction cannot exceed 30% of the calculated time.
Additional Time for Previous Nonconformities
Where auditors must assess corrections or corrective actions relating to previous nonconformities, each nonconformity should be treated as a separate task under Measurement, Analysis and Improvement.
Additional audit time should be allocated accordingly.
Critical Suppliers Can Increase Audit Time
The AO may add additional time depending on the number of critical suppliers involved.
For manufacturers with complex supply chains, this means supplier criticality can directly affect expected audit duration.
Multiple Sites Must Be Calculated Separately
For multi-site organisations, audit duration must be calculated separately for each site.
The total duration is then the cumulative time required across all sites.
MDSAP explicitly states that sampling of design and manufacturing sites is not permitted.
Each site must therefore be assessed according to its actual responsibilities and processes.
Organisation Size Can Reduce Audit Duration
The procedure allows reductions based on organisation size under defined circumstances.
To qualify, the organisation must generally:
manufacture only lower-risk devices;
use relatively simple designs or manufacturing processes;
have a history of good QMS performance.
Certain High-Risk Activities Are Excluded
Organisation-size reductions do not apply to high-risk products or complex activities.
Excluded examples include:
life-supporting or life-sustaining devices;
implantable devices;
devices involving the central cardiovascular or nervous system;
ionising-radiation devices;
devices incorporating drugs or biologics;
devices containing human or animal tissues;
certain high-risk IVDs;
point-of-care or self-test IVDs, other than pregnancy and fertility tests;
aseptic processing;
certain sterilisation activities.
Audit Time Reductions by Employee Count
Where the qualifying criteria are met, the procedure provides defined reduction factors.
These include:
1–5 employees: −42%;
6–10 employees: −39%;
11–15 employees: −35%;
16–25 employees: −28%;
26–45 employees: −18%;
46–65 employees: −14%;
66–85 employees: −10%;
86–100 employees: −5%.
The table on page 10 visually summarises these employee-based adjustment factors.
Surveillance Audits Continue to Follow a Three-Year Cycle
Appendix 1 provides detailed guidance on surveillance audits.
The purpose of the surveillance programme is to ensure that all applicable requirements of:
ISO 13485:2016;
participating Regulatory Authorities
are covered during the manufacturer’s three-year audit cycle.
Key Surveillance Objectives
Surveillance audits evaluate:
continued effectiveness of the QMS;
implementation of corrective actions;
ongoing regulatory compliance;
new or changed technologies;
updated technical documentation;
post-market safety and effectiveness information.
They also review issues such as:
complaints;
problem reports;
vigilance reports;
recalls;
field corrections;
advisory notices.
Stage 1 Is Normally Not Required for Surveillance
Surveillance audits generally do not require a Stage 1 audit unless significant changes have occurred.
Examples include major QMS changes arising from new or amended legislation.
Not Every Requirement Must Be Audited at Every Surveillance Visit
Each surveillance audit does not need to cover every MDSAP requirement.
However, the full set of applicable requirements must be addressed across the audit cycle.
The appendix provides process-specific tables indicating whether individual audit tasks should be:
audited at every surveillance;
covered in one of the two surveillance audits;
not normally audited during surveillance.
Technical Documentation Must Remain Current
Surveillance audits must also confirm that manufacturers have arrangements in place to maintain current technical documentation for all devices.
This reinforces the expectation that technical documentation remains actively maintained throughout the product lifecycle rather than only at initial certification.
Impact on Medical Device Manufacturers
For manufacturers participating in MDSAP, the updated procedure reinforces that audit duration is not based simply on employee headcount or a fixed number of days.
It depends on factors including:
applicable MDSAP tasks;
type of audit;
number of sites;
design activities;
manufacturing complexity;
previous nonconformities;
critical suppliers;
device risk;
organisation size;
previous audit outcomes.
Manufacturers should therefore expect audit duration to reflect their specific regulatory and operational profile.
Impact on Auditing Organizations
Recognised AOs must ensure that audit time determinations are:
traceable;
justified;
documented;
consistent with the MDSAP methodology.
Any reductions or increases should be supported by documented rationale.
Why the Update Matters
Version 009 does not introduce a completely new audit-duration model.
Instead, it updates the procedure to reflect current references and terminology while maintaining the established task-based MDSAP approach.
For manufacturers, the update provides an opportunity to review how their own audit duration may be calculated and which organisational or product characteristics can increase or reduce expected audit time.